Multiple H. pylori cell targets

The term “Multiple H. pylori cell targets” refers broadly to the numerous and diverse molecular and cellular components of host tissues or the bacterium itself that can be affected during *Helicobacter pylori* infection. *H. pylori* pathogenesis involves interacting with and altering host cell pathways, such as targeting mitochondria (through VacA and non-VacA mechanisms), disrupting signaling via receptor tyrosine kinases (e.g., EPHA2), and promoting DNA damage, cell survival/dysfunction, and inflammation[1][5]. Because *H. pylori* infects and perturbs multiple host cell functions and pathways, no single defined receptor, protein, or molecular structure constitutes "multiple H. pylori cell targets." Consequently, the entry lacks sufficient specificity for direct classification as a drug target or molecular entity suitable for conventional drug-target mapping[1][3][5]. *H. pylori* targets include mitochondrial proteins (e.g., deregulation of mitochondrial DNA polymerase POLG, TFAM, mitochondrial import translocases TOM22/TIM23)[1]. Host receptor tyrosine kinases, particularly EPHA2, are downregulated and perturbed during infection[5]. Eradication therapies act on multiple *H. pylori* enzymes, cell wall components, and survival pathways, rather than a single molecular target[4][6][8].

Antibacterial action targeting multiple bacterial pathways; Inhibition of bacterial DNA synthesis; Disruption of cell wall integrity; Inhibition of bacterial protein synthesis; Alteration of host cell signaling